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ABSTRACT
Rosacea is a chronic inflammatory disease with
transient and non-transient redness as key
characteristics. Brimonidine is a selective
a2-adrenergic receptor (AR) agonist approved
for persistent facial erythema of rosacea based
on significant efficacy and good safety data. The
majority of patients treated with brimonidine
report a benefit; however, there have been
sporadic reports of worsening erythema after
the initial response. A group of dermatologists,
receptor physiology, and neuroimmunology
scientists met to explore potential mechanisms
contributing to side effects as well as differences
in efficacy. We propose the following could
contribute to erythema after application: (1)
local inflammation and perivascular
inflammatory cells with abnormally
functioning ARs may lead to vasodilatation;
(2) abnormal saturation and cells expressing
different AR subtypes with varying ligand
affinity; (3) barrier dysfunction and increased
skin concentrations of brimonidine with
increased actions at endothelial and
presynaptic receptors, resulting in increased
vasodilation; and (4) genetic predisposition
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and receptor polymorphism(s) leading to
different smooth muscle responses.
Approximately 80% of patients treated with
brimonidine experience a significant
improvement without erythema worsening as
an adverse event. Attention to optimizing skin
barrier function, setting patient expectations,
and strategies to minimize potential problems
may possibly reduce further the number of
patients who experience side effects.
Funding: Galderma International S.A.S., Paris,
France.
Keywords: Adrenergic receptors; Brimonidine;
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INTRODUCTION
Transient and non-transient erythema are key
characteristics of rosacea. Up to 85% of
individuals with rosacea suffer from facial
redness [1]; managing this redness poses a
challenge for patients and clinicians alike [2].
Rosacea-related erythema can have short or
long durations, and may take many forms,
including persistent underlying redness,
transient erythema (flushing) that is triggered
by stimuli, or redness associated with individual
inflammatory lesions or telangiectasias [2–4].
Relatively little is understood about the
mechanisms that cause of redness, but both
vascular and inflammatory events are involved
[5–9]. Neurogenic inflammation may have a
role; in this case, dysregulated neurovascular
communication may lead to sustained
vasodilation induced by various trigger factors
(e.g., spicy food, exercise, heat, etc.) and
thereby prolong flushing (±stinging/burning).
Neurologic factors also can influence vascular
responses, and both sensory and autonomic
nerves interact with immune cells in the process
of flushing. Non-transient erythema of rosacea
could represent a form of neurogenic
inflammation, with immune mediators
released by endothelial cells, keratinocytes,
and immune cells resulting in chronic
inflammation. Or, pathogens may activate
innate immune receptors, such as toll-like
receptor-2 (TLR-2) and upregulate
antimicrobial peptides, such as cathelicidin
LL37. LL37 can induce inflammation and
vascular responses, and stimulate the release of
cytokines and other mediators that secondarily
activate neurovascular changes [10, 11].
Topical brimonidine gel 0.33% is approved
to treat rosacea-associated redness [12, 13]. This
agent selectively binds a2-adrenergic receptors
(ARs) on vascular smooth muscle resulting in
local transient vasoconstriction following
topical application. Approximately 80% of
patients treated with brimonidine report
redness relief [14]. As the effects of
brimonidine wear off (typically 10–12 h after
application), erythema is expected to slowly
return to baseline. In post-marketing
experience, there were some reports of a
transient worsening erythema rather than a
return to baseline levels manifesting as [15–17]:
• Paradoxical erythema—redness appearing
within 6 h after the application of
brimonidine (can be worse than baseline).
• Exaggerated recurrence of erythema—
redness greater than baseline that occurs as
therapy wears off (10–12 h post-application).
• Allergic contact dermatitis—redness (usually
accompanied by other signs, such as eczema
and pruritus) occurring several months after
the initiation of therapy.
Side effects were not reported in publications
of the pivotal clinical trials as ‘‘paradoxical
erythema;’’ however, Holmes et al. [18]
conducted an analysis of adverse events and
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stated 3.6% of subjects reported erythema and
1.8% flushing during the phase 3 study; in the
long-term study, 9.1% of subjects had flushing
and 6.5% had erythema. Tanghetti et al. [15]
estimated that 10–20% of patients are at risk for
worsening of redness. Jackson et al. [19] state ‘‘in
our clinics, approximately 4–15% of patients have
complained of worsening erythema or flushing,’’
adding that while this led to discontinuation of
drug for some, many patients were able to
successfully continue treatment, because
‘‘worsening of erythema was only temporary
and not a daily issue.’’ Furthermore, they noted
that erythema typically occurred during the
initiation of therapy and subsided with regular
use [19]. In response to a case report published in
2016, Tanghetti agreed, noting ‘‘Once the
paradoxical erythema subsided, some patients
were able to resume therapy without recurrence
of this problem’’ [55].
We discuss physiologic mechanisms that
may contribute to worsening erythema (Fig. 1).
In our opinion, the most likely candidates are:
• Local inflammation with perivascular
inflammatory cells bearing increased or
modified brimonidine-responsive ARs, leading
to increaseddrugeffect to releasemediatorsand
produce sustained vasodilatation (Fig. 1).
• High concentration of brimonidine in the skin
(e.g., due to skin barrier dysfunction).
Brimonidine may penetrate in higher
concentrations to endothelium and nerve
terminals to cause vasodilatation (Figs. 1, 2).
• Abnormal saturation effects and inhibited
release of norepinephrine (NE) from
sympathetic nerve terminals due to the
Local Inflammaon
with modified receptors
More mediators released            Dilaon
Local inflammaon
with increased number
of receptors as targets
More mediators
released
Dilaon
Increased drug concentraon
due to barrier disrupon
(drug penetrates further)
Genec polymorphism
Inhibion of 
norepinephrine
release
Leads to vasodilaon
Drug penetrates to
endothelium
endothelium-dependent
dilaon (possibly 
mediated by NO)
Fig. 1 Rosacea. Schematic representation of possible mechanisms that contribute to the exacerbation of erythema during
brimonidine therapy. NO nitric oxide
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action of brimonidine on a2-ARs, with a net
effect of reduced NE availability.
• Genetic polymorphism(s) for genes increase the
affinity of brimonidine to the receptor,
resulting in increased smooth muscle
responses and sustained vasodilation.
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
BRIEF REVIEW OF ADRENERGIC
RECEPTOR FUNCTIONS
Overview
Review of receptor physiology is helpful to
understand what may be affecting the action of
brimonidine. G protein-coupled receptors
(GPCRs), including ARs, interact with
catecholamines, particularly NE and
epinephrine. ARs are found throughout the
body, including in the vascular smooth muscle,
vascular endothelium, on presynaptic nerve
terminals, and on a subset of immune cells.
There are a number of subtypes based on
physiologic function, pharmacology, structure,
and signal transduction (Fig. 2) [20]. The
function of a-ARs in the skin is primarily to
regulate blood flow through vasoconstriction
following catecholamine binding to receptors on
vascular smooth muscle, where the mobilization
of calcium stores results in muscle cell
contraction. Detailed molecular mechanisms of
ARs are described elsewhere [21].
Factors that Affect Receptor Function
a 2 Receptors
a-ARs are divided into a1 and a2 subtypes. The
relative contribution of a1 and a2 subtypes in
subcutaneous vessels can vary with location,
receptor density, local NE concentration, and
temperature [20, 22, 23]. The density of arterial
Fig. 2 Rosacea. Possible sites of adrenergic receptors in the
control of vascular tone: (1) post-synaptic a-ARs on
vascular smooth muscle, (2) post-synaptic a-ARs on
vascular endothelium, (3) pre-synaptic a2-ARs on nerve
terminals, and (4) post-synaptic b-ARs on vascular smooth
muscles
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a2-ARs increases from proximal to distal
location [20], and a2-ARs are thought to
dominate in small vessels (\200 microns) [24].
Expression of a-ARs on non-smooth muscle
cells can also mediate receptor function. Within
the vasculature, a2-ARs on endothelial cells
relax blood vessels by release of nitric oxide
(NO) [25], an effect opposite that of ARs on
vascular smooth muscle. Presynaptic nerve
terminals likewise express a2-ARs and induce
vasorelaxation by inhibiting release of NE and,
subsequently, adrenergic neurotransmission via
a negative feedback function [26].
a 1 Receptors
Sensory nerve fibers have also been shown to
express a1-ARs, which generate axon-reflex
vasodilation peripheral to the area of
vasoconstriction [27]. The more recently
described a1D-AR may be the most important
receptor in terms of sympathetic nervous
control of arteries, as it predominates at the
sympathetic neuroeffector junction [28].
Receptor Expression on Immune Cells
Finally, several immune cell subsets present in
the skin express a1- and a2-ARs. a1-ARs are
expressed on cells with known
pro-inflammatory activities, whereas a2-ARs
appear to mediate anti-inflammatory effects
[29, 30].
ADRENERGIC RECEPTORS:
SPECULATIONS ABOUT ROLE
IN ROSACEA
AND WITH BRIMONIDINE THERAPY
Rosacea is a disease of chronic, cyclic
inflammation, and vasodilation. a-ARs in skin
of selected rosacea patients may exhibit an
altered physiological response to brimonidine
that may be dependent or independent of the
disease or the agonist. Possible factors that may
contribute to episodes of worsening erythema
are discussed below.
Impact of Concentration and/or Chronic
Agonism
In rosacea patients, epidermal barrier function
is disturbed and stratum corneum hydration is
reduced [31, 32]. This may lead to higher drug
concentrations in skin and possibly also altered
drug clearance. Differences in application
techniques can affect the distribution of
brimonidine and local drug concentrations.
Local brimonidine concentrations may
influence worsening erythema by: (1) the
saturation of a2-receptors on vascular smooth
muscle, resulting in the binding of additional
cell types or AR subtypes and/or (2) the chronic
agonism of a-ARs, resulting in the
downregulation and desensitization of
receptors.
Brimonidine is a selective a2A-AR agonist, but
it exhibits a reduced affinity for a2C- and
a1A-ARs as well [24]. Binding to the more
recently characterized a1D subtype was not
tested, but may also occur when brimonidine
is present at high concentrations. The effect of
brimonidine on other receptors or cell types
might be concentration dependent, and a
spillover effect after saturation of the a2A-AR
on vascular smooth muscle could occur.
Increased local concentrations (‘spillover
effect’) may allow brimonidine to act on at
least one endothelial receptor (a2A-AR and other
subtypes), thereby promoting NO-mediated
vasodilation. Brimonidine may also act on
presynaptic ARs of nerve terminals leading to
reduced vasoconstriction (a2A- and
a2C-mediated). Both effects could promote
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local vasodilation (a2-mediated) and worsen
erythema.
a2A-ARs expressed on presynaptic nerves
modulate an intense, acute release of NE that is
evoked by high-frequency neuronal stimulation
occurring with stress responses. In contrast,
a2C-ARs on presynaptic nerve terminals regulate
the basal, long-term release of NE due to
low-frequency stimulation. Thus, these
receptors tightly regulate neurotransmitter
release from adrenergic nerves under basal and
stressful conditions through their inhibitory
presynaptic feedback loop.
Taken together, differences in sympathetic
nerve firing rates, and thus local NE
concentrations, could impact brimonidine
efficacy by competing for a2-AR binding.
Neuronal activation could also lead to release
of other neuromediators that induce
vasodilation. For example, axon-reflex
vasodilation mediated by a1-ARs is partially
mediated by prostaglandins (which have been
shown to be increased in rosacea skin) and the
overall activity has been suggested to contribute
to local vascular disturbances in acute or chronic
inflammation. Furthermore, a1-ARs have been
found in subpopulations of neurons in rat skin,
which are immunoreactive to the TRPV1
(transient receptor potential cation channel
subfamily V member 1) ion channel and the
neuromediator calcitonin gene-related peptide
(CGRP; glucagon-related peptide), both of which
are involved in vasodilation and neurogenic
inflammation in human rosacea skin [6, 33, 34].
Enhanced concentration of brimonidine
may also result in the activation of a1-ARs
present on immune cells, such as macrophages
and mast cells, both of which are present at
increased densities in rosacea-affected skin.
Known effects include an increased release of
vasodilatory mediators, such as prostaglandin
E2, histamine, tryptase, and neuropeptides,
which could in turn result in worsened
erythema [35].
The ‘spillover’ effect may explain
paradoxical-worsening erythema following the
application of brimonidine, where an initial
reduction in erythema is observable prior to the
saturation of vascular a2-ARs. This may be
followed by enhanced binding to other
receptor subtypes on different cell types that
override local vasoconstriction by vasodilatory
and/or inflammatory mechanisms within a few
hours of application.
Alternatively, chronic a2-AR agonism may
downregulate or desensitize vasoconstrictive
a2-ARs, leading to reflexive vasodilation via
vasodilatatory a-ARs. This hypothesis is
supported by the fact that similar feedback
loops have been demonstrated with other a
adrenergic agonists, e.g., rhinitis
medicamentosa induced by nasally
administered oxymetazoline and
xylometazoline [36]. However, the adaptation
of receptors with chronic ophthalmic use has
not been reported, and minimal to no
tachyphylaxis has been reported with chronic
topical use [12].
To minimize the potential for complications
related to concentration and skin barrier
function, we agree with the recommendations
by Tanghetti et al. [15] to set realistic patient
expectations by providing clear education, to
teach patients to apply the medication in a very
thin layer initially, and to make the first trial of
medication on a day when the patient is able to
observe the effect in privacy.
Impact of Inflammation
Rosacea is characterized by abnormal
inflammatory responses to regular
environmental stimuli (e.g., ultraviolet light
and microbes) mediated by abnormally
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increased neuromediators [37, 38], proteases,
cytokines, vitamin D, and TLR-2 signaling
[8, 9, 33, 39]. TLR-2 signaling can recruit a
variety of inflammatory mediators, many of
which are regulated by the transcription factor
NF-kB, such as interleukin-6 (IL-6) or tumor
necrosis factor-a (TNF-a) [6, 9, 40].
An NF-kB binding site in the promoter
region of G protein receptor kinase (GRKs)
could be involved in shifting GPCR signaling
[41]. These kinases are well known to regulate
GPCR cell function, including receptor
internalization and desensitization, thereby
leading to reduced receptor numbers (by
downregulation) as well as alternate signaling
via recruitment of b-arrestin [42]. Moreover,
shifts in AR signaling have been linked to the
induction of inflammation by increasing NF-kB
levels [43–51]. This could be a possible
mechanism for the adverse rebound effect
observed in some patients using brimonidine.
Mast cells may contribute to the
inflammatory loop in rosacea as well. Mast
cell-deficient mice do not display rosacea-like
inflammation [52, 53], and a adrenergic
blockade increases acetylcholine release as well
as subsequent pituitary adenylate
cyclase-activating polypeptide (PACAP) release
and protease-activated receptor 2 (PAR2)
activation, contributing to inflammation and
vasodilation. The stimulation of neuropeptide
release by innate immune receptors, such as
TLR2 and PAR2, may be critically involved in
inflammatory vasodilation, as observed in all
three skin subtypes of rosacea [6, 7].
COX-2 and prostaglandin production, both
of which are elevated in rosacea, may increase
a-receptor-mediated NO, thereby contributing
to vasodilation and edema via a
prostanoid-dependent pathway. Furthermore,
the effects of brimonidine treatment may be
different in the early versus late inflammation,
as immune and vascular responses can shift
with prolonged stimuli, thereby changing the
repertoire and density of ARs and GPCRs.
Skin deposits of nitrogen (NO2 and NO3) are
converted to NO and promote vasodilation
independent of the endothelium in the
presence of ultraviolet A irradiation, a
common trigger in rosacea.
An inflammatory milieu and heightened
neuronal activity are present in rosacea [7, 9],
and it is possible that worsening erythema
could represent an exaggerated compensatory
neuroinflammatory mechanism of the
vasculature aside from what is suggested here,
such as release of neuropeptides and systemic
adrenergic or other vasoactive peptides.
Best results may be obtained when
rosacea-associated inflammation is managed
using the traditional rosacea treatments in
conjunction with brimonidine therapy. Using
brimonidine to reduce the overall erythema can
unmask redness from inflammatory lesions,
which is unpalatable for patients. It may also
be useful to educate patients about overall facial
erythema, telangiectasias, and perilesional
erythema [15].
Impact of Genetic Polymorphisms
Genetic polymorphism in ARs is common and
may cause lack of or reduced functional
receptor subtypes on vascular smooth muscle
in some individuals. Polymorphisms in the
receptors may produce differential binding,
altered binding sensitivity, or receptor
distribution. The impact of polymorphism on
ARs is evidenced by the drug response to
albuterol (salbutamol) in asthma, where it has
been demonstrated that responses to
receptor-blocking drugs can change [54].
Polymorphic differences in avidity or altered
kinetics among a2A-ARs expressed on different
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tissues may also explain the worsening
erythema phenomenon, particularly with
regard to exaggerated recurrence as drug effect
wanes. If the avidity of brimonidine for the
a2-AR on presynaptic nerve terminals is greater
than that on vascular smooth muscle, the
vasoconstrictive effect on vessels may wear off
as expected, but negative feedback inhibition
on nerve terminals may remain for a longer
period, with transiently sustained erythema.
This potential mechanism also underscores
the prudence of advising patients to make the
first trial of medication on the weekend or a day
when the patient can be comfortable even in
the unlikely event that worsening erythema
occurs [15].
SUMMARY AND CONCLUSIONS
Brimonidine has proven strong vasoconstrictive
effects on a2-ARs of vessels and—to a lesser
extent—on a1-ARs [24]. In rosacea, ARs on other
tissues—such as endothelium, presynaptic
adrenergic nerve terminals, and immune
cells—may also promote vasodilation. Skin
reactivity to adrenergic agonists may be
influenced by a complex system of activation
and inhibition, systemic factors, such as
epinephrine/NE levels, local tissue factors
(including NO), receptor up- and
downregulations, desensitization,
inflammation, and exterior (e.g., temperature,
ultraviolet light, microbes, and proteases) or
endogenous factors (increase of local body
temperature via exercising, pH changes,
microbiota). In turn, worsening erythema
events may occur with brimonidine use for
reasons that are entirely patient dependent and
can be allergic (very rarely) or non-allergic
(more often) on nature.
The worsening phenomenon that occurs in
some patients as the effects of brimonidine
agonism wane may be explained by receptor
desensitization and internalization, negative
feedback loops, or activation of other
compensatory mediators that lead to
vasodilation. Skin barrier dysfunction can
increase local concentrations of brimonidine
and can be effectively treated with moisturizers
prior to brimonidine therapy. In addition, the
paradoxical-worsening phenomenon occurring
within hours of brimonidine application may
be explained by high concentrations of
brimonidine within skin that leads to the
saturation of receptors and ‘spillover’ effect to
other a-AR subtypes with unwanted effects
(vasodilation).
Brimonidine effects are predominantly
beneficial. We hypothesize that certain
individual characteristics may potentially
override the vasoconstrictive effect transiently
(e.g., barrier dysfunction) or permanently (e.g.,
receptor polymorphisms). Future studies are
important to define those subgroups that may
are most likely to benefit from brimonidine,
since it is the first efficacious topical treatment
against a frequent—and often challenging to
treat—symptom in rosacea. It is crucial for
clinicians to educate patients who should be
taught to start with a very thin layer of
medication and to use other strategies that can
optimize brimonidine therapy [15].
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